TY - JOUR
T1 - Modulation of the opioid growth factor ([Met 5]-enkephalin)- opioid growth factor receptor axis
T2 - Novel therapies for squamous cell carcinoma of the head and neck
AU - McLaughlin, Patricia J.
AU - Stucki, Jaimon K.
AU - Zagon, Ian S.
PY - 2012/4/1
Y1 - 2012/4/1
N2 - Background The opioid growth factor (OGF)-OGF receptor (OGFr) axis is a constitutively expressed biologic pathway regulating cell proliferation of squamous cell carcinoma of the head and neck (SCCHN). This study investigated modulation of the OGF-OGFr system by (1) exogenous OGF, (2) upregulation of OGFr using imiquimod, or (3) intermittent opioid receptor blockade with a low dose of naltrexone on progression of established SCCHN. Methods Nude mice with visible human SCCHN SCC-1 tumors received (1) OGF or low-dose naltrexone either 1, 3, or 7 times/week or (2) imiquimod 1 or 3 times/week. Tumor growth and DNA synthesis were monitored. Results OGF and low-dose naltrexone increased the latency from visible to measurable tumors up to 1.6-fold. OGF, low-dose naltrexone, and imiquimod treatment markedly reduced tumor volume and weight, and decreased DNA synthesis in tumors. Conclusions Modulation of the native OGF-OGFr regulatory network in SCCHN represents a novel nontoxic and highly efficacious approach for treatment of SCCHN.
AB - Background The opioid growth factor (OGF)-OGF receptor (OGFr) axis is a constitutively expressed biologic pathway regulating cell proliferation of squamous cell carcinoma of the head and neck (SCCHN). This study investigated modulation of the OGF-OGFr system by (1) exogenous OGF, (2) upregulation of OGFr using imiquimod, or (3) intermittent opioid receptor blockade with a low dose of naltrexone on progression of established SCCHN. Methods Nude mice with visible human SCCHN SCC-1 tumors received (1) OGF or low-dose naltrexone either 1, 3, or 7 times/week or (2) imiquimod 1 or 3 times/week. Tumor growth and DNA synthesis were monitored. Results OGF and low-dose naltrexone increased the latency from visible to measurable tumors up to 1.6-fold. OGF, low-dose naltrexone, and imiquimod treatment markedly reduced tumor volume and weight, and decreased DNA synthesis in tumors. Conclusions Modulation of the native OGF-OGFr regulatory network in SCCHN represents a novel nontoxic and highly efficacious approach for treatment of SCCHN.
UR - http://www.scopus.com/inward/record.url?scp=80052798281&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80052798281&partnerID=8YFLogxK
U2 - 10.1002/hed.21759
DO - 10.1002/hed.21759
M3 - Article
C2 - 21584896
AN - SCOPUS:80052798281
SN - 1043-3074
VL - 34
SP - 513
EP - 519
JO - Head and Neck Surgery
JF - Head and Neck Surgery
IS - 4
ER -